Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era
暂无分享,去创建一个
A. Vignati | M. Ponzoni | A. Ferreri | S. Govi | L. Scarfò | M. Foppoli | G. Citterio | M. Sassone | G. Donadoni | Marta Bruno-Ventre | F. Caligaris‐cappio
[1] C. Rübe,et al. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. , 2014, Blood.
[2] W. Wilson,et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma , 2014, Haematologica.
[3] A. Ferreri. Risk of CNS dissemination in extranodal lymphomas. , 2014, The Lancet. Oncology.
[4] S. Montoto,et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology , 2013, British journal of haematology.
[5] J. Delabie,et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Avilés,et al. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: An analysis of 3,258 patients in a single center , 2013, Medical Oncology.
[7] K. Imrie,et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B‐cell lymphoma treated in the rituximab era: a single centre experience and review of the literature , 2012, British journal of haematology.
[8] A. Ferreri. How I treat primary CNS lymphoma. , 2011, Blood.
[9] K. Morris,et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2011, Cancer.
[10] J. Jazbec,et al. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma , 2011, European Journal of Clinical Pharmacology.
[11] P. Hammerman,et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2010, Cancer.
[12] K. Gatter,et al. Diffuse large B-cell lymphoma , 2010 .
[13] A. Ferreri,et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options , 2009, Hematological oncology.
[14] S. Kvaløy,et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] N. Schmitz,et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Justine R. Smith,et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. , 2003, Blood.
[18] S. Kvaløy,et al. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. , 2000, European journal of cancer.
[19] H. Tilly,et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .
[20] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. Yeh,et al. Systemic chemotherapy alone for patients with non‐acquired immunodeficiency syndrome‐related central nervous system lymphoma , 1998, Cancer.
[22] G. Snow,et al. The role of radiotherapy , 1980, The Journal of Laryngology & Otology.
[23] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[24] D. Nan,et al. Incidence and Risk Factors , 2015 .
[25] A. Skotnicki,et al. Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas. , 2013, Polskie Archiwum Medycyny Wewnetrznej.
[26] T. Molina,et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[28] H. Tilly,et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.